ArticleFrontiers in oncology2025
Pancreatic hepatoid adenocarcinoma with neuroendocrine differentiation and elevated AFP: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imaging of pancreatic hepatoid adenocarcinoma: a scoping review.Quantitative imaging in medicine and surgery · 2026Review
- Alpha-Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC): A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Marked response to dabrafenib plus trametinib in a patient with BRAF V600E-mutant pancreatic hepatoid carcinoma: a case report and systematic analysis of 57 cases.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatoid adenocarcinoma (HAC) of the pancreas is a rare malignant tumor characterized by morphologic and immunophenotypic features resembling hepatocellular carcinoma. The tumor cells exhibit polygonal morphology with eosinophilic or clear cytoplasm and large, irregular nuclei. Immunophenotypically, the tumor cells are positive for alpha-fetoprotein (AFP) and glypican-3. Pancreatic HAC is rare, and neuroendocrine differentiation often complicates both diagnosis and treatment. Case description: We report a case of pancreatic HAC with neuroendocrine differentiation and elevated AFP levels. A 46-year-old man was hospitalized due to progressive jaundice and dark urine that persisted for a week. Physical examination revealed bile duct dilation, a pancreatic head mass, and markedly increased AFP levels. The patient, with a history of schizophrenia and lung cancer surgery 2 years prior, was on regular medication. Following a pancreaticoduodenectomy, postoperative monitoring indicated normalization of AFP levels. Conclusion: Elevated serum AFP levels may be a crucial indicator for preoperative pancreatic HAC diagnosis. Additionally, pancreatic HAC has unique histological and immunophenotypic characteristics. However, neuroendocrine differentiation complicates diagnosis and treatment. Therefore, complete surgical resection is the optimal treatment option for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.